The Profound Impacts of Precision Medicine, Genomic Sequencing on Cancer Care

Precision Oncology is helping NCI treat cancer based on specific genetic changes in a patient’s tumor by allowing them to target mutations that will lower toxicity and improve overall effectiveness of the treatment.
A clinical trial at the National Cancer Institute called NCI-MATCH showed how cancer patients could benefit from genomic sequencing and is now informing future trials on precision medicine.
The NCI Molecular Analysis for Therapy Choice Trial initially screened 6,000 patients and treated 1,300 of them by pairing certain medications with their specific tumors regardless of the cancer type. Future trials like ComboMATCH will now look at precision medicine to study how tumors respond to targeted treatments.
NCI Researchers Dr. Lindsay Harris and Dr. Peter O’Dwyer shared how precision oncology is expanding treatment options and increasing patients’ survival rates. They also discuss the importance of clinical trials like these for progressing the fight against cancer.

-
Dr. Lyndsay Harris Associate Director, Cancer Diagnosis Program NCI
-
Dr. Peter O'Dwyer Group Co-Chair ECOG-ACRIN Cancer Research Group
-
AFCEA West: AI is America’s ‘Sputnik Moment,’ Defense Academic Says
NPS president says that ‘warrior scholars’ bridge research and implementable capabilities for national security.
12m listen -
Defending the Cyber Domain in a Time of 'Non-Kinetic' Threats
Northcom's intelligence leader Brig. Gen. Maurizio Calabrese discussed the evolving role of defense intelligence technology.
20m watch -
The Year Ahead: FBI’s 2025 Cybersecurity Priorities
The FBI is increasing awareness of vulnerabilities and employing AI-enabled tools to secure networks from sophisticated cyber threats.
25m listen -
OPM Navigates AI Governance Through People
OPM's Taka Ariga explores AI's role in an efficient federal workforce and operations, focusing on trust, data integrity and storytelling.
19m listen